The Synthetic Standard
Thursday, September 18th, 2025
Daily Artificial Intelligence
Loading...

More

Yankees Place Aaron Judge on 10-Day IL with Toe Injury 2:11AM
PGA Tour Announces Shock Reconciliation with Saudi-Backed LIV Golf and DP World Tour 2:08AM
Top Stories This Week in Essex County: From Caldwells to Montclair 6:13PM
Debt Ceiling Talks Hit a Snag, Negotiations Paused Between White House and House Republicans 3:57PM
Blue Origin Wins NASA Contract to Develop Crewed Lunar Lander for Artemis Program 2:40PM
D.C. Police Lieutenant Indicted for Obstruction and Making False Statements in Connection with Proud Boys Leader 1:58PM
Denver Business Journal Announces Small Business Awards Finalists and Winner 1:31PM
Tesco Chairman John Allan Resigns Amid Allegations of Inappropriate Behaviour 1:16PM
Morgan Stanley CEO James Gorman to Step Down, Succession Race Begins 12:42PM
Foot Locker Shares Plummet 25% as Company Cuts Annual Forecasts 11:47AM
The Synthetic Standard
Stay up to date with the latest stories

Get a daily newsletter delivered straight to your inbox with the top stories of the day.

Publication

  • About
  • Staff
  • Archive
  • Contact

Legal

  • Privacy Policy
  • Terms & Conditions

The content on this site was not created under human supervision. No warranty, express or implied, is made as to the truth, accuracy, or completeness of the information provided. Readers are advised to verify any information independently before relying on it.

© 2025 The Synthetic Standard. All Rights Reserved.

Twitter page
March 28, 2023

Allarity Outlines Steps to Accelerate Delayed Recruitment in Ixempra, Stenoparib Cancer Trials

Allarity Outlines Steps to Accelerate Delayed Recruitment in Ixempra, Stenoparib Cancer Trials
Emery Taylor
Emery Taylor

Allarity Therapeutics, a biotechnology company focused on developing targeted cancer treatments, has announced its plans to accelerate the recruitment process for its delayed clinical trials of Ixempra and Stenoparib.

The trials were initially scheduled to begin earlier this year but have been delayed due to the ongoing COVID-19 pandemic. The company has outlined several steps that it will take to expedite the recruitment process and get the trials back on track.

"We understand that delays in clinical trials can be frustrating for patients and their families," said Steve Carchedi, CEO of Allarity Therapeutics. "That's why we are taking proactive measures to move these important studies forward as quickly as possible."

One of the key steps being taken by Allarity is an expansion of the geographic scope of patient recruitment efforts. The company plans to broaden its reach beyond current trial sites in order to identify more eligible patients who may be interested in participating.

Additionally, Allarity will be implementing virtual screening procedures which will allow potential participants greater access while minimizing exposure risks during the pandemic.

"By leveraging technology and expanding our outreach efforts, we hope to bring together a diverse group of patients from around the world," added Carchedi. "This will help us gather more comprehensive data which could ultimately lead us closer towards finding effective treatments for those battling cancer."

Allarity remains committed towards advancing its mission and bringing innovative solutions into oncology research despite challenges caused by COVID-19. By outlining these steps today, they show how dedicated they are towards speeding up clinical trials that can potentially save millions of lives around the globe.